WO2002018595A3 - Moraxella polypeptides and corresponding dna fragments and uses thereof - Google Patents

Moraxella polypeptides and corresponding dna fragments and uses thereof Download PDF

Info

Publication number
WO2002018595A3
WO2002018595A3 PCT/CA2001/001221 CA0101221W WO0218595A3 WO 2002018595 A3 WO2002018595 A3 WO 2002018595A3 CA 0101221 W CA0101221 W CA 0101221W WO 0218595 A3 WO0218595 A3 WO 0218595A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
omp
proteins
moraxella
catarrhalis
Prior art date
Application number
PCT/CA2001/001221
Other languages
French (fr)
Other versions
WO2002018595A9 (en
WO2002018595A2 (en
Inventor
Sheena Loosmore
Joe Wang
Bill Bradley
Martina Ochs
Yan-Ping Yang
Original Assignee
Aventis Pasteur
Sheena Loosmore
Joe Wang
Bill Bradley
Martina Ochs
Yan-Ping Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU8743001A priority Critical patent/AU8743001A/en
Application filed by Aventis Pasteur, Sheena Loosmore, Joe Wang, Bill Bradley, Martina Ochs, Yan-Ping Yang filed Critical Aventis Pasteur
Priority to AU2001287430A priority patent/AU2001287430A1/en
Publication of WO2002018595A2 publication Critical patent/WO2002018595A2/en
Publication of WO2002018595A3 publication Critical patent/WO2002018595A3/en
Publication of WO2002018595A9 publication Critical patent/WO2002018595A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides nucleic acids, proteins and vectors for immunization of a host, including humans, against disease caused by infection by a strain of Moraxella, specifically M. catarrhalis. The invention includes DNA vaccination methods which employ a vector containing a nucleotide sequence encoding a protein of a strain of Moraxella, specifically M. catarrhalis, and a promoter to effect expression of the protein gene product in the host. The nucleotide sequences include those which encode: a major anaerobically induced OMP, rare lipoprotein A proteins, component proteins of the adhesin complex, a potential lipoprotein OMP, a putative oxidoreductase, OprM, collagenase, outer membrane phopholipase A, lipoproteins, OmpA, NADH:ubiquinone oxidoreductase subunit, pilQ fimbriae, invasin protein, a 36 kDa secreted protein, OMP, Outer membrane esterase, pyridine nucleotide transhydrogenase, HecB, a putative virulence factor, heme receptor, ompC, heme receptor, and porin.
PCT/CA2001/001221 2000-08-28 2001-08-28 Moraxella polypeptides and corresponding dna fragments and uses thereof WO2002018595A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU8743001A AU8743001A (en) 2000-08-28 2001-08-24 Moraxella polypeptides and corresponding dna fragments and uses thereof
AU2001287430A AU2001287430A1 (en) 2000-08-28 2001-08-28 Moraxella polypeptides and corresponding dna fragments and uses thereof

Applications Claiming Priority (54)

Application Number Priority Date Filing Date Title
US22829500P 2000-08-28 2000-08-28
US22829400P 2000-08-28 2000-08-28
US22829600P 2000-08-28 2000-08-28
US60/228,294 2000-08-28
US60/228,296 2000-08-28
US60/228,295 2000-08-28
US22844000P 2000-08-29 2000-08-29
US22851100P 2000-08-29 2000-08-29
US22851200P 2000-08-29 2000-08-29
US22844100P 2000-08-29 2000-08-29
US22843900P 2000-08-29 2000-08-29
US22844300P 2000-08-29 2000-08-29
US22877300P 2000-08-29 2000-08-29
US22843800P 2000-08-29 2000-08-29
US22844200P 2000-08-29 2000-08-29
US22874200P 2000-08-29 2000-08-29
US60/228,442 2000-08-29
US60/228,440 2000-08-29
US60/228,439 2000-08-29
US60/228,438 2000-08-29
US60/228,512 2000-08-29
US60/228,441 2000-08-29
US60/228,443 2000-08-29
US60/228,511 2000-08-29
US60/228,773 2000-08-29
US60/228,742 2000-08-29
US22946500P 2000-09-01 2000-09-01
US22947500P 2000-09-01 2000-09-01
US22947400P 2000-09-01 2000-09-01
US22947800P 2000-09-01 2000-09-01
US60/229,475 2000-09-01
US60/229,474 2000-09-01
US60/229,478 2000-09-01
US60/229,465 2000-09-01
US22980600P 2000-09-05 2000-09-05
US22980500P 2000-09-05 2000-09-05
US22981100P 2000-09-05 2000-09-05
US22980900P 2000-09-05 2000-09-05
US22980300P 2000-09-05 2000-09-05
US22974000P 2000-09-05 2000-09-05
US22980400P 2000-09-05 2000-09-05
US60/229,803 2000-09-05
US60/229,809 2000-09-05
US60/229,804 2000-09-05
US60/229,740 2000-09-05
US60/229,806 2000-09-05
US60/229,811 2000-09-05
US60/229,805 2000-09-05
US23025200P 2000-09-06 2000-09-06
US23025000P 2000-09-06 2000-09-06
US23021400P 2000-09-06 2000-09-06
US60/230,214 2000-09-06
US60/230,252 2000-09-06
US60/230,250 2000-09-06

Publications (3)

Publication Number Publication Date
WO2002018595A2 WO2002018595A2 (en) 2002-03-07
WO2002018595A3 true WO2002018595A3 (en) 2002-10-03
WO2002018595A9 WO2002018595A9 (en) 2007-08-23

Family

ID=27586817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001221 WO2002018595A2 (en) 2000-08-28 2001-08-28 Moraxella polypeptides and corresponding dna fragments and uses thereof

Country Status (2)

Country Link
AU (2) AU8743001A (en)
WO (1) WO2002018595A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025754A3 (en) * 2001-05-15 2009-05-13 ID Biomedical Corporation Moraxella (Branhamella) catarrhalis antigens
CA2464957A1 (en) 2001-11-16 2003-05-30 Shire Biochem Inc. Polypeptides of moraxella (branhamella) catarrhalis
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ES2561483T3 (en) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa GAS57 mutant antigens and GAS57 antibodies
JP5656642B2 (en) 2007-12-21 2015-01-21 ノバルティス アーゲー A mutant form of streptolysin O
EA018068B1 (en) 2008-03-03 2013-05-30 Айрм Ллк Compounds and compositions as tlr activity modulators
EP2385842A1 (en) 2009-01-12 2011-11-16 Novartis AG Cna_b domain antigens in vaccines against gram positive bacteria
ES2658863T3 (en) 2009-06-10 2018-03-12 Glaxosmithkline Biologicals Sa Vaccines containing benzonaphthyridine
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators
JP5988492B2 (en) 2009-09-02 2016-09-07 ノバルティス アーゲー Immunogenic composition comprising a TLR activity modulator
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (en) 2009-12-15 2017-12-26 Novartis Ag homogeneous suspension of immunopotentiation compounds and uses of these
JP5848748B2 (en) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ Compounds (cysteine-based lipopeptides) and compositions as TLR2 agonists for use in the treatment of infectious diseases, inflammation, respiratory diseases, etc.
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
GB201102091D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
JP6411378B2 (en) 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Intradermal delivery of an immunological composition comprising a TOLL-like receptor agonist
BR112020016314A2 (en) 2018-02-12 2020-12-15 Inimmune Corporation PHARMACEUTICALLY ACCEPTABLE COMPOUNDS OR SALTS, PHARMACEUTICAL COMPOSITION, KIT, AND, METHODS FOR ELICITATING, INTENSIFYING OR MODIFYING AN IMMUNOLOGICAL RESPONSE, TO TREAT, PREVENT OR REDUCE THE SUSCETIBILITY TO CANCER, TO REDUCE, UNDERSTAND TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AN ALLERGY, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY TO AUTOIMMUNE AFFECTION, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY IN A SUBJECT TO BACTERIAL INFECTION, ALTERNATE, VENEER, NAVAL, NAVARI TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AUTOIMMUNITY, ALLERGY, ISCHEMIA OR SEPSIS REPERFUSION, TO TREAT, PREVENT OR REDUCE THE GRAVITY OF EPILETIC ATTACKS AND TO TREAT, PREVENT OR REDUCE THE MACANTIC HERITAGE OF HERITAGE,
WO2022096596A1 (en) 2020-11-04 2022-05-12 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808024A (en) * 1995-05-01 1998-09-15 Connaught Lab Nucleic acids encoding high molecular weight major outer membrane protein of moraxella
WO2000018910A1 (en) * 1998-10-01 2000-04-06 Antex Biologics Inc. Moraxella catarrhalis protein, nucleic acid sequence and uses thereof
WO2000078968A2 (en) * 1999-06-18 2000-12-28 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome
WO2001019996A1 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Biologicals S.A. Moraxella catarrhalis antigen, corresponding gene and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808024A (en) * 1995-05-01 1998-09-15 Connaught Lab Nucleic acids encoding high molecular weight major outer membrane protein of moraxella
WO2000018910A1 (en) * 1998-10-01 2000-04-06 Antex Biologics Inc. Moraxella catarrhalis protein, nucleic acid sequence and uses thereof
WO2000078968A2 (en) * 1999-06-18 2000-12-28 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome
WO2001019996A1 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Biologicals S.A. Moraxella catarrhalis antigen, corresponding gene and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERARD T. HOEHN ET AL.: "Isolation and nucleotide sequence of the gene (aniA) encoding the major anaerobically induced outer membrane protein of Neisseria gonorrhoeae", INFECTION AND IMMUNITY, vol. 60, no. 11, November 1992 (1992-11-01), WASHINGTON US, pages 4695 - 4703, XP002195482 *
GERARD T. HOEHN ET AL.: "The Major anaerobically induced outer membrane protein of Neisseria gonorrhoeae, Pan 1, is a lipoprotein", INFECTION AND IMMUNITY, vol. 60, no. 11, November 1992 (1992-11-01), WASHINGTON US, pages 4704 - 4708, XP002195483 *

Also Published As

Publication number Publication date
AU2001287430A8 (en) 2002-03-13
WO2002018595A9 (en) 2007-08-23
WO2002018595A2 (en) 2002-03-07
AU2001287430A1 (en) 2002-03-13
AU8743001A (en) 2002-03-13

Similar Documents

Publication Publication Date Title
WO2002018595A3 (en) Moraxella polypeptides and corresponding dna fragments and uses thereof
Hansson et al. Design and production of recombinant subunit vaccines
Lindenthal et al. Identification of a glycoprotein produced by enterotoxigenic Escherichia coli
Koizumi et al. Leptospiral immunoglobulin-like proteins elicit protective immunity
Suzuki et al. Extracellular Transport of VirG Protein in Shigella (∗)
Wilhelm et al. A vaccine against the salmonid pathogen Piscirickettsia salmonis based on recombinant proteins
US5427788A (en) Pertussis toxin and use in vaccines
Batteiger et al. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis
EP1177301B1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
US5571718A (en) Cloning and expression of soluble truncated variants of Borrelia OspA, OspB and Vmp7
CN1290174A (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
JP2005247868A (en) Immunogenic detoxified mutant e. coli lt-a toxin
ATE348892T1 (en) CHLAMYDIA ANTIGENS, CORRESPONDING DNA FRAGMENTS AND THEIR USES
Lo Genetic analysis of virulence factors of Mannheimia (Pasteurella) haemolytica A1
US8114971B2 (en) Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells
Belloy et al. Characterization of LppS, an adhesin of Mycoplasma conjunctivae
CN101175856A (en) Novel genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
Minnick et al. Characterization and expression of the cbbE′ gene of Coxiella burnetii
WO2001074863A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
Simons et al. Localization and function of FanH and FanG, minor components of K99 fimbriae of enterotoxigenic Escherichia coli
Lee et al. Identification of the gene encoding BmpB, a 30 kDa outer envelope lipoprotein of Brachyspira (Serpulina) hyodysenteriae, and immunogenicity of recombinant BmpB in mice and pigs
CA2365196A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2002211201B2 (en) aopB Gene, protein, homologs, fragments and variants thereof, and their use for cell surface display
Kozarov et al. Expression and immunogenicity of hemagglutinin A from Porphyromonas gingivalis in an avirulent Salmonella enterica serovar typhimurium vaccine strain
Zagursky et al. Identification of a Haemophilus influenzae 5′-nucleotidase protein: cloning of the nucA gene and immunogenicity and characterization of the NucA protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP